Historical abt News Stories
Abbott Q1 Beat, Exact Sciences Deal Reshapes Today
Abbott’s Q1 results beat revenue expectations as medical devices offset nutrition weakness. The closing of the Exact Sciences acquisition repositions Abbott toward cancer diagnostics but introduces near‑term EPS dilution and integration risks. Libre 3 sensor recall and a 52‑week low in ABT stock remain investor focal points.
Abbott Closes Exact Sciences; Libre Drives Growth.
Abbott completed its $23B acquisition of Exact Sciences, adding Cologuard and Oncotype DX while accelerating oncology test ordering via Flatiron integration. Combined with robust FreeStyle Libre momentum, nutrition recovery, favorable FreeDM2 clinical results, and a sizable buyback plan, these concrete developments reshape Abbott’s near-term revenue profile and investor thesis.
Abbott: NEC Trial Opens; Exact Sciences Deal Nears
Abbott (ABT) faces a Chicago NEC trial while securing a $20B bond to fund the Exact Sciences acquisition. Recent moves—India diabetes pact, dividend hike, insider buying—shape investor risk and opportunity.
Abbott Rally: Insider Buys and Exact Sciences Deal
Abbott (ABT) faced a volatile week: strong insider buying coincided with advancements in the Exact Sciences acquisition, while Q4 revenue weakness and ongoing FreeStyle Libre regulatory issues pressured the stock. This article breaks down the concrete events shaping ABT’s near-term outlook and what investors should monitor next.
Abbott's India GLP-1 Deal Drives ABT Stock Rebound
Abbott’s partnership with Novo Nordisk India to launch a branded semaglutide (Extensior®) and a modest share rally have shifted investor focus for ABT. Coupled with regulatory progress on the Exact Sciences tie-up, insider buying and a dividend increase, these concrete events are driving renewed confidence in Abbott’s growth trajectory.
Abbott Stock: Libre Recall, Dividends & Targets Q1
Recent analyst target cuts, a Class I FreeStyle Libre recall with reported injuries, and a maintained dividend have created a mixed outlook for Abbott (ABT). This article reviews concrete developments over the past week, their operational impact, and what investors should monitor next.
Abbott FreeStyle Libre 3 Recall Hits ABT Stock Now
A Class 1 FDA recall of nearly 3 million FreeStyle Libre 3 sensors and reports of serious injuries and deaths have intensified pressure on Abbott (ABT). The recall, tied to manufacturing issues found at Abbott’s Alameda facility, has already weighed on the stock and raises questions about near-term Diabetes Care revenue, regulatory scrutiny, and investor confidence.
Abbott Slide: Q4 Miss, Guidance Cuts Hurt ABT Now!
ABT fell ~14% after Q4 revenue missed and management trimmed guidance. MedTech held up, but Nutrition and Diagnostics shortfalls, analyst target trims, and a dividend raise shaped recent moves.